Andrassy Martin, Belov Dmitry, Harja Evis, Zou Yu Shan, Leitges Michael, Katus Hugo A, Nawroth Peter P, Yan Shi Du, Schmidt Ann Marie, Yan Shi-Fang
Department of Surgery, College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.
Circ Res. 2005 Mar 4;96(4):476-83. doi: 10.1161/01.RES.0000156903.37007.d1. Epub 2005 Jan 20.
We tested the hypothesis that PKCbeta contributes to vascular smooth muscle cell (SMC) migration and proliferation; processes central to the pathogenesis of restenosis consequent to vascular injury. Homozygous PKCbeta null (-/-) mice or wild-type mice fed the PKCbeta inhibitor, ruboxistaurin, displayed significantly decreased neointimal expansion in response to acute femoral artery endothelial denudation injury compared with controls. In vivo and in vitro analyses demonstrated that PKCbetaII is critically linked to SMC activation, at least in part via regulation of ERK1/2 MAP kinase and early growth response-1. These data highlight novel roles for PKCbeta in the SMC response to acute arterial injury and suggest that blockade of PKCbeta may represent a therapeutic strategy to limit restenosis.
我们验证了蛋白激酶Cβ(PKCβ)促进血管平滑肌细胞(SMC)迁移和增殖的假说;这些过程是血管损伤后再狭窄发病机制的核心。与对照组相比,纯合PKCβ基因敲除(-/-)小鼠或喂食PKCβ抑制剂鲁比前列酮的野生型小鼠在急性股动脉内皮剥脱损伤后内膜增生明显减少。体内和体外分析表明,PKCβII与SMC激活密切相关,至少部分是通过调节细胞外信号调节激酶1/2(ERK1/2)丝裂原活化蛋白激酶和早期生长反应因子-1实现的。这些数据凸显了PKCβ在SMC对急性动脉损伤反应中的新作用,并表明阻断PKCβ可能是限制再狭窄的一种治疗策略。